JP2019522984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522984A5 JP2019522984A5 JP2018567933A JP2018567933A JP2019522984A5 JP 2019522984 A5 JP2019522984 A5 JP 2019522984A5 JP 2018567933 A JP2018567933 A JP 2018567933A JP 2018567933 A JP2018567933 A JP 2018567933A JP 2019522984 A5 JP2019522984 A5 JP 2019522984A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- cell
- acid sequence
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 81
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 60
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims description 33
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 210000004698 lymphocyte Anatomy 0.000 claims description 11
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 230000002463 transducing effect Effects 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 108010036972 HLA-A11 Antigen Proteins 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 101710177291 Gag polyprotein Proteins 0.000 claims description 2
- 102100034353 Integrase Human genes 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010078428 env Gene Products Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108010089520 pol Gene Products Proteins 0.000 claims description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357265P | 2016-06-30 | 2016-06-30 | |
| US62/357,265 | 2016-06-30 | ||
| PCT/US2017/040448 WO2018006054A1 (en) | 2016-06-30 | 2017-06-30 | Herv-e reactive t cell receptors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522984A JP2019522984A (ja) | 2019-08-22 |
| JP2019522984A5 true JP2019522984A5 (enExample) | 2020-08-06 |
| JP7046016B2 JP7046016B2 (ja) | 2022-04-01 |
Family
ID=59381696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567933A Active JP7046016B2 (ja) | 2016-06-30 | 2017-06-30 | Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11779603B2 (enExample) |
| EP (1) | EP3478711B1 (enExample) |
| JP (1) | JP7046016B2 (enExample) |
| KR (1) | KR102461926B1 (enExample) |
| CN (1) | CN109415429B (enExample) |
| AU (1) | AU2017286982B2 (enExample) |
| DK (1) | DK3478711T3 (enExample) |
| NZ (1) | NZ749585A (enExample) |
| WO (1) | WO2018006054A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111100185A (zh) * | 2018-10-26 | 2020-05-05 | 上海锐赛生物技术有限公司 | Ct-rcc herv-e来源的ctl表位肽、肽库及其应用 |
| CN113710697A (zh) | 2019-03-15 | 2021-11-26 | 美国政府(由卫生和人类服务部的部长所代表) | 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途 |
| WO2021194495A1 (en) | 2020-03-26 | 2021-09-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd28h domain-containing chimeric antigen receptors and methods of use |
| WO2023044304A1 (en) | 2021-09-15 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| WO2025064539A1 (en) * | 2023-09-19 | 2025-03-27 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Herv-e antibodies and methods of their use |
| CN118620059B (zh) * | 2024-02-21 | 2025-08-15 | 北京永泰瑞科生物科技有限公司 | 一种t细胞抗原受体及其制备方法和其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| EP1224291A1 (en) * | 1999-10-28 | 2002-07-24 | Universite De Geneve | Multiple sclerosis-related superantigen |
| DE10019075B4 (de) * | 2000-04-18 | 2007-01-18 | Vision 7 Gmbh | Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker |
| US7820174B2 (en) * | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| WO2007109583A2 (en) * | 2006-03-17 | 2007-09-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject |
| SG173997A1 (en) * | 2006-07-21 | 2011-09-29 | Univ California | Human endogenous retrovirus polypeptide compositions and methods of use thereof |
| CN101528926A (zh) | 2006-08-18 | 2009-09-09 | 肿瘤疗法科学股份有限公司 | 过表达reg4或kiaa0101的癌症的治疗或预防 |
| JP5292550B2 (ja) * | 2007-03-23 | 2013-09-18 | 静岡県 | Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子 |
| JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| EP2618835B1 (en) * | 2010-09-20 | 2017-07-05 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
-
2017
- 2017-06-30 DK DK17742333.2T patent/DK3478711T3/da active
- 2017-06-30 NZ NZ749585A patent/NZ749585A/en unknown
- 2017-06-30 WO PCT/US2017/040448 patent/WO2018006054A1/en not_active Ceased
- 2017-06-30 AU AU2017286982A patent/AU2017286982B2/en active Active
- 2017-06-30 CN CN201780040513.7A patent/CN109415429B/zh active Active
- 2017-06-30 EP EP17742333.2A patent/EP3478711B1/en active Active
- 2017-06-30 US US16/313,712 patent/US11779603B2/en active Active
- 2017-06-30 JP JP2018567933A patent/JP7046016B2/ja active Active
- 2017-06-30 KR KR1020187037984A patent/KR102461926B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522984A5 (enExample) | ||
| US20240093232A1 (en) | Retroviral And Lentiviral Vectors | |
| JP2023060000A (ja) | レトロウイルスおよびレンチウイルスベクター | |
| AU2020211375B2 (en) | Receptors providing targeted costimulation for adoptive cell therapy | |
| JP2012509659A (ja) | 高親和性ｔ細胞受容体およびその用途 | |
| JP2019536461A5 (enExample) | ||
| RU2018136607A (ru) | Способы и составы для производства лимфоцитов и их регулируемого увеличения | |
| JP2019050826A (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| US9670459B2 (en) | Production method for cell populations | |
| WO2020163634A1 (en) | Chimeric cytokine receptors | |
| JPWO2011024791A1 (ja) | レチノイン酸存在下でのｔ細胞集団の製造方法 | |
| US20240024477A1 (en) | T cell receptors and uses thereof | |
| Yang et al. | A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors | |
| Lyu et al. | A novel and simple method to produce large amounts of recombinant soluble peptide/major histocompatibility complex monomers for analysis of antigen-specific human T cell receptors | |
| CN112143707A (zh) | 一种治疗自身免疫细胞的免疫细胞及其应用 | |
| McBride et al. | Applications of molecular engineering in T‐cell‐based immunotherapies | |
| KR102757789B1 (ko) | 쥐 불변 영역을 갖는 tcr을 발현하는 세포를 선택적으로 확대시키는 방법 | |
| WO2012096376A1 (ja) | 制御性ｔ細胞の製造方法 | |
| JP5485139B2 (ja) | 遺伝子導入細胞の製造方法 | |
| Yin et al. | Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+ T cells by TCR gene transfer | |
| Field et al. | Engineered T cell therapies | |
| US20250228939A1 (en) | Enhanced immune cell therapy | |
| WO2024222701A1 (zh) | 一种t细胞受体及其用途 | |
| Ha | CD4+ T cell mediated tumor immunity following transplantation of TRP-1 TCR gene modified hematopoietic stem cells |